Cryolife Inc (NYSE:CRY) has been assigned a consensus recommendation of “Buy” from the six research firms that are covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold recommendation, three have given a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $31.33.
A number of equities research analysts have commented on CRY shares. Canaccord Genuity raised their price target on shares of Cryolife from $28.00 to $36.00 and gave the stock a “buy” rating in a report on Wednesday. Northland Securities restated a “buy” rating and issued a $32.00 price target on shares of Cryolife in a report on Tuesday, August 7th. ValuEngine upgraded shares of Cryolife from a “buy” rating to a “strong-buy” rating in a report on Wednesday, May 23rd. Finally, Zacks Investment Research upgraded shares of Cryolife from a “sell” rating to a “hold” rating in a report on Wednesday, May 2nd.
Shares of CRY traded down $0.30 during trading hours on Tuesday, hitting $32.85. 262,340 shares of the stock were exchanged, compared to its average volume of 116,955. Cryolife has a fifty-two week low of $16.80 and a fifty-two week high of $34.15. The company has a quick ratio of 3.72, a current ratio of 4.97 and a debt-to-equity ratio of 0.80. The stock has a market cap of $1.22 billion, a PE ratio of 82.13 and a beta of 0.73.
Cryolife (NYSE:CRY) last posted its quarterly earnings data on Monday, August 6th. The medical equipment provider reported $0.10 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.07 by $0.03. Cryolife had a negative net margin of 2.34% and a positive return on equity of 4.28%. The company had revenue of $68.50 million during the quarter, compared to analysts’ expectations of $64.08 million. During the same period in the prior year, the company posted $0.12 earnings per share. Cryolife’s revenue for the quarter was up 43.2% compared to the same quarter last year. sell-side analysts anticipate that Cryolife will post 0.31 EPS for the current fiscal year.
In other Cryolife news, Director C Elkins Ronald sold 10,000 shares of the firm’s stock in a transaction on Monday, May 14th. The shares were sold at an average price of $24.75, for a total value of $247,500.00. Following the transaction, the director now directly owns 78,997 shares of the company’s stock, valued at $1,955,175.75. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, VP John E. Davis sold 4,373 shares of the firm’s stock in a transaction on Wednesday, May 16th. The shares were sold at an average price of $27.00, for a total transaction of $118,071.00. Following the completion of the transaction, the vice president now directly owns 55,811 shares in the company, valued at $1,506,897. The disclosure for this sale can be found here. Insiders sold 39,028 shares of company stock worth $1,096,606 over the last ninety days. Insiders own 3.97% of the company’s stock.
Several institutional investors have recently added to or reduced their stakes in CRY. Zurcher Kantonalbank Zurich Cantonalbank raised its position in Cryolife by 117.0% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,305 shares of the medical equipment provider’s stock worth $176,000 after acquiring an additional 3,400 shares during the period. Metropolitan Life Insurance Co. NY bought a new stake in Cryolife in the fourth quarter worth about $203,000. United Services Automobile Association bought a new stake in Cryolife in the second quarter worth about $208,000. NewFocus Financial Group LLC bought a new stake in Cryolife in the second quarter worth about $218,000. Finally, Piedmont Investment Advisors LLC bought a new stake in Cryolife in the second quarter worth about $220,000. 67.46% of the stock is currently owned by hedge funds and other institutional investors.
CryoLife, Inc, together with its subsidiaries, manufactures, processes, and distributes medical devices and implantable human tissues for use in cardiac and vascular surgeries worldwide. The company operates in two segments, Medical Devices and Preservation Services. It offers BioGlue, an agent for cross-linking proteins for cardiac, vascular, pulmonary, and general surgical applications; On-X mechanical heart valves for aortic and mitral indications; cardiac preservation services; PhotoFix, a bovine pericardial patch for use in cardiac and vascular repairing activities; and PerClot, an absorbable powdered hemostat for use in surgical procedures, including cardiac, vascular, orthopedic, neurological, gynecological, ENT, and trauma surgeries.
Receive News & Ratings for Cryolife Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cryolife and related companies with MarketBeat.com's FREE daily email newsletter.